Gland Pharma Limited (NSE: GLAND), an injectable-focused pharmaceutical company, announced its financial results for the first quarter and year ended June 30th, 2026. Commenting on the results, Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Our strong start to FY27 reflects the successful execution of our CDMO strategy and the resilience of our B2B business model. Growth was driven by recent product launches from CDMO portfolio and strong customer demand for our diversified product mix. We continue to strengthen our growth platform through a robust CDMO pipeline including investments in differentiated technologies and capacity expansions, which position us well for sustainable long-term growth.”

Financial Highlights

The consolidated financial performance for Q1 FY27 showed significant growth across various metrics:

• Quarterly revenue increased by 20% year-on-year.

• Quarterly R&D investments stood at ₹ 772 million.

• Quarterly adj. EBITDA increased by 37% year-on-year.

• Quarterly adj. EBITDA margin stood at 28%.

• Quarterly PAT increased by 47% year-on-year.

• Quarterly PAT margin increased by ~330 bps year-on-year.

Business Segment Performance

The company’s business segments also performed strongly:

• CDMO business contributed 50% of revenues and grew by 20% year-on-year in Q1FY27.

• B2B* business contributed 50% of revenues and grew by 19% year-on-year in Q1FY27. Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.

As the company continues to leverage its strategic initiatives, it is well-positioned for continued growth and success in the upcoming quarters.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gland Pharma Limited

Gland Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Gland gains 36.6% over three months and trades near its 52-week highs. The PEG stands at 4.24 — severely stretched. Any earnings miss could trigger a sharp de-rating. Revenue grows at 21.4% and profits at 9.6% CAGR. The market consistently rewards this kind of compounding. The stock trades at 97% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 21.4% and profits at 9.6%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 4.24 premium is usually justified. Check Fundamentals of Gland Pharma Limited.

Gland Pharma Limited (NSE: GLAND) announced the execution of a strategic Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for the Technology Transfer, Manufacturing and Supply of a portfolio of sterile injectable products for global markets. This partnership establishes Gland Pharma as an integrated end-to-end partner supporting multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development. The collaboration follows a full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.

Comprehensive ‘One-Stop’ Solution

Under the agreement, Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality, and regulatory support to provide a comprehensive ‘one-stop’ solution to its partner. The agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The current agreement covers 55 SKUs to be manufactured across three sites, with the scope of adding more products soon. Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million.

Strategic Milestone

The partnership represents an important milestone in Gland Pharma’s growth journey and further strengthens its position as a trusted global CDMO partner for pharmaceutical companies seeking a full-service model including integrated development, technology transfer, and manufacturing solutions for sterile injectable products. Mr. Srinivas Sadu, Executive Chairman, Gland Pharma Limited, said: “We are pleased to enter into this strategic collaboration. The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma’s development, technology transfer, manufacturing, and supply capabilities. The agreement provides meaningful long-term revenue visibility, supports expansion of our CDMO business, and creates a strong foundation for future growth. We remain committed to investing in the capabilities and capacity required to support our partner’s evolving needs and ensure reliable supply to patients worldwide.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gland Pharma Limited

Gland Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Gland gains 36.6% over three months and trades near its 52-week highs. The PEG stands at 4.24 — severely stretched. Any earnings miss could trigger a sharp de-rating. Revenue grows at 21.4% and profits at 9.6% CAGR. The market consistently rewards this kind of compounding. The stock trades at 97% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 21.4% and profits at 9.6%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 4.24 premium is usually justified. Check Fundamentals of Gland Pharma Limited.

Gland Pharma Limited (GLAND) announced a long-term strategic collaboration with Neuland Laboratories to expand sterile API manufacturing through a new cGMP state-of-the-art sterile suite. The partnership aims to combine Neuland’s complex API development and manufacturing capabilities with Gland Pharma’s global sterile manufacturing expertise to meet the growing worldwide demand for sterile APIs used in microparticle depot products and other complex sterile APIs.

Strategic Expansion

Under the partnership, Gland Pharma will establish a sterile manufacturing suite for Active Pharmaceutical Ingredients (APIs) pertaining to microparticle depot products. This collaboration represents a significant expansion of the relationship between the two companies, creating a dedicated manufacturing platform that aligns their complementary capabilities under a long-term strategic partnership.

Enhanced Manufacturing Infrastructure

Gland Pharma will expand its existing sterile manufacturing infrastructure through an additional dedicated suite at its JNPC facility at Visakhapatnam to support Neuland for its growing demand of sterile APIs. The facility will be constructed and operated to cGMP, USFDA, and EU standards, backed by Gland Pharma’s proven aseptic manufacturing expertise. Together, the companies will offer an integrated CDMO solution encompassing development, scale-up, regulatory support, and commercial manufacturing of sterile APIs.

As a result, the suite will be designed to add approximately 1400 kg of annual capacity, providing manufacturing flexibility across multiple sterile products while supporting future growth. The partnership is expected to enhance supply resilience globally by combining Neuland’s development and regulatory expertise with Gland Pharma’s manufacturing capabilities.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gland Pharma Limited

Gland Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Gland gains 42.6% over three months and trades near its 52-week highs. The PEG stands at 4.31 — severely stretched. Any earnings miss could trigger a sharp de-rating. Revenue grows at 21.4% and profits at 9.6% CAGR. The market consistently rewards this kind of compounding. Buyers show up with 1.4x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. The business grows revenue at 21.4% and profits at 9.6%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 4.31 premium is usually justified. Check Fundamentals of Gland Pharma Limited.